We are live on ! Find out more
APTO

Aptose Biosciences, Inc.
APTO

Delisted

APTO was delisted on the 1st of April, 2025.

Back to rankings

24 hedge funds and large institutions have $1.72M invested in Aptose Biosciences, Inc. in 2024 Q1 according to their latest regulatory filings, with 2 funds opening new positions, 1 increasing their positions, 8 reducing their positions, and 3 closing their positions.

New
Increased
Maintained
Reduced
Closed

4% less funds holding

Funds holding: 25 → 24 (-1)

33% less first-time investments, than exits

New positions opened: 2 | Existing positions closed: 3

47% less capital invested

Capital invested by funds: $3.25M → $1.72M (-$1.53M)

88% less repeat investments, than reductions

Existing positions increased: 1 | Existing positions reduced: 8

Holders
24
Holders Change
-1
Holders Change %
-4%
% of All Funds
0.35%
Holding in Top 10
–
Holding in Top 10 Change
–
Holding in Top 10 Change %
–
% of All Funds
–
New
2
Increased
1
Reduced
8
Closed
3
Calls
–
Puts
–
Net Calls
–
Net Calls Change
–

Top Buyers

Rank Fund Capital Flow
1
SPC
Sigma Planning Corp
Michigan
+$212K
2
Cetera Investment Advisers
Cetera Investment Advisers
Illinois
+$40.7K
3
PP
PDS Planning
Ohio
+$19.1K

Top Sellers

Rank Fund Capital Flow
1
Morgan Stanley
Morgan Stanley
New York
-$277K
2
CC
Carlson Capital
Texas
-$246K
3
AC
Annandale Capital
Texas
-$91.5K
4
Citadel Advisors
Citadel Advisors
Florida
-$69.1K
5
NCM
Nantahala Capital Management
Connecticut
-$60.2K
Name Holding Trade Value Shares
Change 		Change in
Stake
DS
1
DRW Securities
Illinois
$984K – – –
SPC
2
Sigma Planning Corp
Michigan
$309K +$212K +3,698 +147%
NCM
3
Nantahala Capital Management
Connecticut
$147K -$60.2K -1,053 -26%
Morgan Stanley
4
Morgan Stanley
New York
$56.3K -$277K -4,834 -81%
AC
5
Annandale Capital
Texas
$44K -$91.5K -1,600 -64%
Citadel Advisors
6
Citadel Advisors
Florida
$42.6K -$69.1K -1,207 -59%
Cetera Investment Advisers
7
Cetera Investment Advisers
Illinois
$35.4K +$40.7K +711 New
CA
8
Cetera Advisors
Colorado
$35.4K -$5.78K -101 -12%
TCBWMS
9
Texas Capital Bank Wealth Management Services
Texas
$20.7K – – –
PP
10
PDS Planning
Ohio
$16.6K +$19.1K +333 New
TWC
11
TD Waterhouse Canada
Ontario, Canada
$15.4K – – –
US Bancorp
12
US Bancorp
Minnesota
$3.35K – – –
GG
13
Gleason Group
Kentucky
$2.02K – – –
Royal Bank of Canada
14
Royal Bank of Canada
Ontario, Canada
$2K -$10.2K -179 -80%
NFSG
15
Newbridge Financial Services Group
Florida
$1.38K – – –
Osaic Holdings
16
Osaic Holdings
Arizona
$697 – – –
HWM
17
HighMark Wealth Management
Minnesota
$498 – – –
BHWM
18
Beaird Harris Wealth Management
Texas
$415 – – –
Northwestern Mutual Wealth Management
19
Northwestern Mutual Wealth Management
Wisconsin
$221 -$400 -7 -64%
FDCDDQ
20
Federation des caisses Desjardins du Quebec
Quebec, Canada
$219 – – –
Group One Trading
21
Group One Trading
Illinois
$191 – – –
CSC
22
Caldwell Sutter Capital
California
$153 – – –
Wells Fargo
23
Wells Fargo
California
$120 – – –
Bank of America
24
Bank of America
North Carolina
$110 -$57 -1 -33%
PCWA
25
Pacific Capital Wealth Advisors
California
$10 – – –
1
2

APTO Hedge Fund Activity: Q1 2024 in Review

24 of the 6,942 institutional investors tracked by Wall St. Rank reported a position in Aptose Biosciences, Inc. (APTO) for Q1 2024, worth a combined $1.72M — down 47% from $3.25M a quarter earlier.

Sellers outnumbered buyers: 3 funds closed out of APTO and 2 opened new positions — a net loss of 1 holder — while 8 trimmed existing stakes and 1 added.

The largest buyer was Sigma Planning Corp, adding an estimated $212K. The largest seller was Morgan Stanley, cutting an estimated $277K.

  • 24 institutional investors held Aptose Biosciences, Inc. (APTO) as of Q1 2024, down from 25 in Q4 2023.
  • Funds reported $1.72M of Aptose Biosciences, Inc. stock for Q1 2024, down 47% quarter-over-quarter.
  • 2 funds opened new Aptose Biosciences, Inc. positions in Q1 2024 and 3 closed out, a net change of -1 holder.
  • The largest Aptose Biosciences, Inc. buyer in Q1 2024 was Sigma Planning Corp, an estimated $212K added.
  • The largest Aptose Biosciences, Inc. seller in Q1 2024 was Morgan Stanley, an estimated $277K sold.

Based on aggregated 13F filings for Q1 2024.